<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368285">
  <stage>Registered</stage>
  <submitdate>20/04/2015</submitdate>
  <approvaldate>4/06/2015</approvaldate>
  <actrnumber>ACTRN12615000586516</actrnumber>
  <trial_identification>
    <studytitle>Thymine test for 5-fluorouracil side effects</studytitle>
    <scientifictitle>An observational case-control study to detect predisposition to 5-fluorouracil/capecitabine-related toxicity using a thymine test in gastrointestinal cancer patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastrointestinal cancers</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Small bowel (duodenum and ileum)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants are administered a single dose of thymine (250 mg, orally)  at any time prior to, or after completion of, a cycle of 5-fluorouracil/capecitabine treatment course.
A cumulative 4 h urine sample is collected for detemination of the amount of thymine and metabolites excreted
 </interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether the ratio of thymine to metabolites detected in the urine sample after the thymine test dose can discriminate between patients who tolerate 5-FU/capecitabine treatment and those who experience severe toxicity.</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>SNP variants of genes associated with abberrant 5-FU disposition, such as didhydropyrimidine dehydrogenase, will be assessed to detemine if any of these correlate with inter-individual differences in the thymine ratio detected in urine</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients diagnosed with histologically confirmed gastrointestinal cancer; about to start or have commenced therapy with single agent 5FU or capecitabine</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnant or breast feeding; concurrent adbominopelvic radiation therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Case control</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/04/2015</anticipatedstartdate>
    <actualstartdate>21/04/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Auckland</primarysponsorname>
    <primarysponsoraddress>The University of Auckland Private Bag 92019. Auckland Mail Centre Auckland 1142. </primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname> School of Medicine Foundation, University of Auckland and Genesis Oncology Trust</fundingname>
      <fundingaddress>The University of Auckland Private Bag 92019. Auckland Mail Centre Auckland 1142. </fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>not applicable</sponsorname>
      <sponsoraddress>not applicable</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to determine whether the thymine test can appropriately characterise a patients ability to tolerate 5FU treatment. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern A Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/11/2014</ethicapprovaldate>
      <hrec>14/NTA/186</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Nuala Helsby</name>
      <address>Molecular Medicine and Pathology
FMHS, University of Auckland
85 Park Road,
Grafton
Auckland</address>
      <phone>+6499239831</phone>
      <fax />
      <email>n.helsby@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Nuala Helsby</name>
      <address>Molecular Medicine and Pathology
FMHS, University of Auckland
85 Park Road,
Grafton
Auckland</address>
      <phone>+6499239831</phone>
      <fax />
      <email>n.helsby@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Nuala Helsby</name>
      <address>Molecular Medicine and Pathology
FMHS, University of Auckland
85 Park Road,
Grafton
Auckland</address>
      <phone>+6499239831</phone>
      <fax />
      <email>n.helsby@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>